UB Paderborn / Katalog / Suche / in CDI

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

The lancet oncology, 2021-10, Vol.22 (10), p.1403-1415

2021

Volltextzugriff (PDF)

Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

Scientific reports, 2019-07, Vol.9 (1), p.10634-10634, Article 10634

2019

Volltextzugriff (PDF)

DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

Clinical cancer research, 2015-04, Vol.21 (7), p.1614-1620

2015

Volltextzugriff (PDF)

Real world CAR T cell data in diffuse large B-cell lymphoma: hitting a moving target

Leukemia & lymphoma, 2022-07, Vol.63 (9), p.2019-2020

2022

Volltextzugriff (PDF)

Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu

Experimental cell research, 2010-12, Vol.316 (20), p.3417-3424

2010

Volltextzugriff (PDF)

Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients

Clinical infectious diseases, 2021-10, Vol.73 (7), p.1257-1265

2021

Volltextzugriff (PDF)

The Yeast RSC Chromatin-Remodeling Complex Is Required for Kinetochore Function in Chromosome Segregation

Molecular and Cellular Biology, 2003-05, Vol.23 (9), p.3202-3215

2003

Volltextzugriff (PDF)

Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience

Journal of immunotherapy (1997), 2022-06, Vol.45 (5), p.254

2022

Volltextzugriff (PDF)

Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant

Leukemia & lymphoma, 2020-10, Vol.61 (12), p.2894-2899

2020

Volltextzugriff (PDF)

Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes

Leukemia & lymphoma, 2022-01, Vol.63 (2), p.435-442

2022

Volltextzugriff (PDF)

Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

Scientific reports, 2020-07, Vol.10 (1), p.12733-12733, Article 12733

2020

Volltextzugriff (PDF)

Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes

Transplantation and cellular therapy, 2021-02, Vol.27 (2), p.142.e1-142.e11

2021

Volltextzugriff (PDF)

Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma

Leukemia & lymphoma, 2021-06, Vol.62 (7), p.1629-1638

2021

Volltextzugriff (PDF)

The RSC Nucleosome-Remodeling Complex Is Required for Cohesin's Association With Chromosome Arms

Molecular cell, 2004-03, Vol.13 (5), p.739-750

2004

Volltextzugriff (PDF)

Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation

Transplantation and cellular therapy, 2023-05, Vol.29 (5), p.326.e1-326.e10

2023

Volltextzugriff (PDF)

Yeast RSC Function Is Required for Organization of the Cellular Cytoskeleton via an Alternative PKC1 Pathway

Genetics (Austin), 2002-06, Vol.161 (2), p.575-584

2002

Volltextzugriff (PDF)

Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response

Blood advances, 2020-10, Vol.4 (20), p.5146-5156

2020

Volltextzugriff (PDF)

Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices

Biology of blood and marrow transplantation, 2018-02, Vol.24 (2), p.288-293

2018

Volltextzugriff (PDF)

NCMP-02. NEUROTOXICITY RELATED TO CAR T-CELL THERAPY IN PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi147-vi147

2021

Volltextzugriff (PDF)

Phase I study of AIC100 in relapsed and/or refractory advanced thyroid cancer and anaplastic thyroid cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.6093-6093

2022

Volltextzugriff (PDF)

High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8021-8021

2021

Volltextzugriff (PDF)

Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes

Biology of blood and marrow transplantation, 2019-03, Vol.25 (3), p.466-473

2019

Volltextzugriff (PDF)

Reply to Caldwell et al

Clinical infectious diseases, 2022-08, Vol.75 (1), p.180-181

2022

Volltextzugriff (PDF)

Abstract 2329: Clinical manufacturing of CAR T cells targeting ICAM-1 for a phase I study against advanced thyroid cancer therapy

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2329-2329

2019

Volltextzugriff (PDF)

Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression

Life science alliance, 2021-02, Vol.4 (2), p.e202000955

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

Real world CAR T cell data in diffuse large B-cell lymphoma: hitting a moving target

Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu

Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients

The Yeast RSC Chromatin-Remodeling Complex Is Required for Kinetochore Function in Chromosome Segregation

Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience

Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant

Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes

Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes

Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma

The RSC Nucleosome-Remodeling Complex Is Required for Cohesin's Association With Chromosome Arms

Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation

Yeast RSC Function Is Required for Organization of the Cellular Cytoskeleton via an Alternative PKC1 Pathway

Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response

Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices

NCMP-02. NEUROTOXICITY RELATED TO CAR T-CELL THERAPY IN PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Phase I study of AIC100 in relapsed and/or refractory advanced thyroid cancer and anaplastic thyroid cancer

High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma

Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes

Reply to Caldwell et al

Abstract 2329: Clinical manufacturing of CAR T cells targeting ICAM-1 for a phase I study against advanced thyroid cancer therapy

Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression

Suchergebnisse filtern